• Je něco špatně v tomto záznamu ?

CCL2, CCL8, CXCL12 chemokines in resectable non-small cell lung cancer (NSCLC)

M. Drosslerova, M. Sterclova, A. Taskova, V. Hytych, E. Richterova, M. Bruzova, M. Spunda, M. Komarc, M. Koziar Vasakova

. 2023 ; 167 (4) : 335-339. [pub] 20230109

Jazyk angličtina Země Česko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23022198

BACKGROUND: Complex networks of chemokines are part of the immune reaction targeted against tumor cells. Chemokines influence cancer growth. It is unclear whether the concentrations of chemokines at the time of NSCLC (non-small cell lung cancer) diagnosis differ from healthy controls and reflect the extent of NSCLC. AIMS: To compare chemokine concentrations (CCL2, CCL8, CXCL12) in the plasma of patients with resectable NSCLC to those without cancer. To determine whether the chemokine concentrations differ relative to the stage of disease. METHODS: Sixty-nine patients undergoing surgery for proven/suspected NSCLC were enrolled. They underwent standard diagnostic and staging procedures to determine resectability, surgery was performed. Forty-two patients were diagnosed with NSCLC, while 27patients had benign lung lesions and functioned as the control group. Chemokine concentrations in peripheral blood were assessed using ELISA. Parametric statistics were used for the analysis of results. RESULTS: There were no differences in plasma chemokine concentrations in NSCLC patients compared to controls. CXCL12 concentrations correlated positively with tumor extent expressed as clinical stage, (mean values: stage I 5.08 ng/mL, SEM 0.59; stage II and IIIA 7.82 ng/mL; SEM 1.06; P=0.022). Patients with NSCLC stages II+IIIA had significantly higher CXCL12 concentrations than controls (mean values: stage II+IIIA 7.82 ng/mL; SEM 1.06; controls 5.3 ng/mL; SEM 0.46; P=0.017). CONCLUSION: CXCL12 was related to tumor growth and could potentially be used as a biomarker of advanced disease.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23022198
003      
CZ-PrNML
005      
20250228133210.0
007      
ta
008      
240104s2023 xr d f 000 0|eng||
009      
AR
024    7_
$a 10.5507/bp.2022.050 $2 doi
035    __
$a (PubMed)36628560
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Drosslerova, Marie $u Department of Respiratory Medicine, 1st Faculty of Medicine, Charles University and Thomayer University Hospital, Videnska 800, 140 00 Prague 4, Czech Republic
245    10
$a CCL2, CCL8, CXCL12 chemokines in resectable non-small cell lung cancer (NSCLC) / $c M. Drosslerova, M. Sterclova, A. Taskova, V. Hytych, E. Richterova, M. Bruzova, M. Spunda, M. Komarc, M. Koziar Vasakova
520    9_
$a BACKGROUND: Complex networks of chemokines are part of the immune reaction targeted against tumor cells. Chemokines influence cancer growth. It is unclear whether the concentrations of chemokines at the time of NSCLC (non-small cell lung cancer) diagnosis differ from healthy controls and reflect the extent of NSCLC. AIMS: To compare chemokine concentrations (CCL2, CCL8, CXCL12) in the plasma of patients with resectable NSCLC to those without cancer. To determine whether the chemokine concentrations differ relative to the stage of disease. METHODS: Sixty-nine patients undergoing surgery for proven/suspected NSCLC were enrolled. They underwent standard diagnostic and staging procedures to determine resectability, surgery was performed. Forty-two patients were diagnosed with NSCLC, while 27patients had benign lung lesions and functioned as the control group. Chemokine concentrations in peripheral blood were assessed using ELISA. Parametric statistics were used for the analysis of results. RESULTS: There were no differences in plasma chemokine concentrations in NSCLC patients compared to controls. CXCL12 concentrations correlated positively with tumor extent expressed as clinical stage, (mean values: stage I 5.08 ng/mL, SEM 0.59; stage II and IIIA 7.82 ng/mL; SEM 1.06; P=0.022). Patients with NSCLC stages II+IIIA had significantly higher CXCL12 concentrations than controls (mean values: stage II+IIIA 7.82 ng/mL; SEM 1.06; controls 5.3 ng/mL; SEM 0.46; P=0.017). CONCLUSION: CXCL12 was related to tumor growth and could potentially be used as a biomarker of advanced disease.
650    _2
$a lidé $7 D006801
650    12
$a nemalobuněčný karcinom plic $x chirurgie $x patologie $7 D002289
650    12
$a nádory plic $x chirurgie $x patologie $7 D008175
650    _2
$a chemokiny $7 D018925
650    _2
$a biologické markery $7 D015415
650    _2
$a chemokin CCL8 $7 D054412
650    _2
$a chemokin CCL2 $7 D018932
650    _2
$a chemokin CXCL12 $7 D054377
655    _2
$a časopisecké články $7 D016428
700    1_
$a Šterclová, Martina, $u Department of Respiratory Medicine, 1st Faculty of Medicine, Charles University and Thomayer University Hospital, Videnska 800, 140 00 Prague 4, Czech Republic $d 1979- $7 xx0108032
700    1_
$a Tašková, Alice, $u Department of Thoracic Surgery, Thomayer University Hospital, Videnska 800, 140 00 Prague 4, Czech Republic $d 1975- $7 pna2014841693
700    1_
$a Hytych, Vladislav, $u Department of Thoracic Surgery, Thomayer University Hospital, Videnska 800, 140 00 Prague 4, Czech Republic $d 1954- $7 xx0077545
700    1_
$a Richterova, Eva $u Department of Pathology and Molecular Medicine, 3rd Faculty of Medicine, Charles University and Thomayer University Hospital, Videnska 800, 140 00 Prague 4, Czech Republic
700    1_
$a Bruzova, Magdalena $u Department of Pathology and Molecular Medicine, 3rd Faculty of Medicine, Charles University and Thomayer University Hospital, Videnska 800, 140 00 Prague 4, Czech Republic
700    1_
$a Špunda, Miloslav, $u Institute of Biophysics and Informatics, First Faculty of Medicine, Charles University, Salmovska 1, 120 00 Prague 2, Czech Republic $d 1942- $7 nlk19990074145
700    1_
$a Komarc, Martin $u Institute of Biophysics and Informatics, First Faculty of Medicine, Charles University, Salmovska 1, 120 00 Prague 2, Czech Republic $7 pna20191026198
700    1_
$a Koziar Vasakova, Martina $u Department of Respiratory Medicine, 1st Faculty of Medicine, Charles University and Thomayer University Hospital, Videnska 800, 140 00 Prague 4, Czech Republic
773    0_
$w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $x 1804-7521 $g Roč. 167, č. 4 (2023), s. 335-339
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36628560 $y Pubmed
910    __
$a ABA008 $b A 1502 $c 958 $y - $z 0
990    __
$a 20240104 $b ABA008
991    __
$a 20250228133203 $b ABA008
999    __
$a ok $b bmc $g 2276361 $s 1208642
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 167 $c 4 $d 335-339 $e 20230109 $i 1804-7521 $m Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $n Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub $x MED00012606
LZP    __
$b NLK116 $a Pubmed-20240104

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...